Abstract:Chronic infection of hepatitis B virus (HBV) is still one of the public health concerns affecting human health. Although the prophylactic HBV vaccines was introduced over three decades ago, the total number of chronic hepatitis B (CHB) infection still accounts for 3.5% (257 million) of the world's population, with approximately 800000 annual deaths related to the viral infection. Currently, drugs including PEG-IFN and NAs are widely used in the treatment of HBV infection with certain degree of success. It is still difficult to achieve a high proportion of "clinical cure" with existing treatment methods. The presence of covalently closed circular DNA (cccDNA) in the infected hepatocytes is the underlying mechanism for the long-term HBV persistence and is also essential for off-therapy viral relapse. The current treatments have no or limited effects on the suppression of intrahepatic cccDNA. The availability for a reliable cccDNA quantification assay would facilitate the developmentof anti-viral drugs targeting cccDNA-targeting. In this review, we summarized the advantages and disadvantages of the existing methods for cccDNA quantitation. Specifically, the extraction method of Hirt DNA combined with Exonuclease V can effectively remove other forms of HBV DNA, and suitable for cccDNA extraction, but it needs to be further optimized. Southern blot is considered as the "gold-standard" method for cccDNA detection, but it is less sensitive and requires cumbersome procedures, making it an unlikely method for high-throughput screening used for drug development or for clinical applications. The PCR-based methods are more convenient and sensitive for cccDNA detection. However, the reliability of PCR-based method requires further optimization and validation. Different PCR-based methods were developed for quantitation of HBV cccDNA. They include selective qPCR, droplet-digital PCR, rolling circle amplification PCR, in situ PCR, invader assay, magnetic capture hybridization qPCR, etc. These PCR-based methods are widely used in clinical and laboratory research for quantitation of cccDNA. Efforts need to be made to minimize the interference from other forms of DNAs in the assays. More recently, hepatitis B core related antigen (HBcrAg)was found to be a novel marker of HBV, and its level in serum is highly correlated with intracellular cccDNA level. This biomarker, the HBcrAg level, can be used to indicate the suppression of cccDNA during different clinical antiviral therapies. The correlation needs further analysis with additional data sets. In summary, we present a review on the quantitation assays for HBV cccDNA. Such assays are important for drug developments and clinical applications for improved management of HBV infection related diseases. Performance and characteristics of various methods were compared with the areas of improvements for different assays.

The influence of nucleos(t)ide analogs on the accuracy of HBV DNA and RNA quantitative detection

Analysis of suspicious results of serum HBV DNA detected by fluorescence quantitative PCR

Evaluation of Nucleic Acid Extraction Methods on HBV DNA Detection by Fluorescence Quantitative PCR (Taqman)

The Relationship of HBV-DNA Quantification and ALT for Type B Hepatitis

The Measurement of HBV DNA in peripheral blood mononuclear cells and its clinical applicability

Improvement of the Analytical Sensitivity of Domestic HBV DNA Kit Based on Magnetic Beads Nucleic Acid Extraction Method

Nucleos(t)ide analogues altered quasispecies composition of hepatitis B virus (HBV)-resistant mutations in serum HBV DNA and serum HBV RNA

Clinical significance of serum HBV RNA measurement in chronic hepatitis B patients

A quantitative method for hepatitis B virus covalently closed circular DNA enables distinguishing direct acting antivirals from cytotoxic agents

Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs

The Clinical Significance of Quantitative Detection of HBV DNA in the Chronic Infected Patients

Correction: Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.

Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy

New advances in drug therapy of chronic hepatitis B infection

Biogenesis of serum HBV RNA and clinical phenomena of serum HBV RNA in chronic hepatitis B patients before and after receiving nucleos(t)ide analogues therapy

Quantitative Detection of HBsAg and HBeAg and Its Correlation with Serum HBV DNA Levels

Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients

Quantatitative Assays For Covalently Closed Circular Dna Of Hepatitis B Virus

The significance of detecting HBV pgRNA and HBcrAg in HBV patients treated with NAs

A Standardized Assay for the Quantitative Detection of Serum HBV RNA in Chronic Hepatitis B Patients.

Serum HBV DNA Plus RNA Shows Superiority in Reflecting the Activity of Intrahepatic Cccdna in Treatment-Naïve HBV-infected Individuals.